Anemia is a state of illness in which the blood is impotent to carry the optimal amount of oxygen owing to severe shortage of hemoglobin or red blood cell (RBC) count. A fundamental decrease in the total hemoglobin or RBC amount is known as anemia. This disease is defined as the inability to carry the optimum amount of oxygen in the blood occurs due to death and shortage of healthy red blood cells. Sickle-Cell Diseases (SCD) are types of red blood cell disorders which are usually inherited genetically. Generally, RBCs are flexible and round in shape, thus, they can move easily through the blood vessels. But in sickle cell anemia, the red blood cell become a rigid, sticky and sickled shape. These unevenly formed red blood cells can get trapped or stuck in blood vessels and block the blood flow eventually resulting in inadequate amount of oxygen to the body. This blockage of oxygen causing pain is termed as sickle cell crisis, which can develop swelling in the limbs, stroke, and microbial infections. Sickle cell anemia treatment helps in releasing problems and pain associated with the disease however in many cases there is no complete cure for this disease. the sickle cell treatment includes medication, bone marrow transplant, and blood transfusions.
The global sickle cell disease treatment market is anticipated to mark a robust growth during the forecast period. The global market is driven by factors such as rising prevalence of sickle cell disease and demand for its proper treatment. For instance, according to the Centers for Disease Control and Prevention (CDC) 2016, Sickle Cell Disease affects approximately 100,000 Americans. Moreover, approximately 1 in 13 African-American babies is born with sickle cell trait (SCT). Another factor responsible for growth in this market is the growing product pipeline for the treatment of the SCD.
In addition, increasing governments focus as well as support on forming awareness on sickle cell disease, increased prevalence of such cases in geriatric population owing to hemorheological changes and rising demand for better diagnosis are boosting the global market growth. Changes in lifestyle result in increased probability of genetic mutations, and factors including increasing presence of FDA approved drugs, rising demand for blood transfusion, decreased cost of diagnosis are responsible for the steady growth of this market. Also, continuous R&D efforts of global key players to form better treatment drugs is another factors bolstering the global sickle cell disease treatment market significantly.
However, unavailability of drugs in rural areas such as Middle East and Africa, lack of reimbursement and high cost of treatment might have a negative impact on the global sickle cell disease treatment market.
The global sickle cell disease treatment market is segmented on the basis of disease type, therapy, drug class, end user, and geography.
On the basis of disease type:
On the basis of therapy:
On the basis of drug class:
On the basis of end user:
Geographically, the sickle cell disease treatment market is segmented into North America, Europe, Asia pacific, Latin America, Middle East, and Africa.
On the basis of geography, North America region is anticipated to dominate the sickle cell disease treatment market. The major market share in this region is driven by factors such as increasing activities in the R&D sector, dynamic healthcare infrastructure, and favorable reimbursement as well as government policies. Moreover, increasing prevalence of sickle cell disease in North American countries and growing demand for early treatment is boosting the market growth in North America. However, Asia Pacific is anticipated to show significant opportunities for global sickle cell disease treatment market. Growing awareness and implementation of treatment for sickle cell disease in developing regions including India is expected to make a remarkable progress of sickle cell disease treatment market.
Key players of global Sickle Cell Disease Treatment market: